Mindset is developing next-generation psychedelic medicines to help treat neuropsychiatric patients with unmet needs.
Advancing an IP portfolio of innovative new psychedelic medicines that leverage clinical research into classic psychedelic drugs:
3 Patents filed on novel chemical structure and synthesis processes;
75 compounds synthesized with preclinical data demonstrating promising results; and
Synthesis process for psilocybin demonstrating clear benefits over known processes.
February 22, 2021Read More
February 19, 2021Read More
February 10, 2021Read More